<DOC>
	<DOCNO>NCT00880217</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety/tolerability 3 different dosage JNJ-31001074 compare placebo adult patient attention-deficit/hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>A Study Evaluate 3 Different Doses JNJ-31001074 Treatment Adults With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither investigator patient know name assign study drug ) , placebo- active-controlled , parallel-group , multicenter study patient adult ADHD . The study population include approximately 426 male female patient , 18 55 year age ( inclusive ) DSM-IV diagnosis ADHD , randomly assign ( like flip coin ) 1:1:1:1:1:1 ratio 1 6 treatment group ( 1 milligram per day [ mg/d ] JNJ-31001074 , 3 mg/d JNJ-31001074 , 10 mg/d JNJ 31001074 , 80 mg/d atomoxetine HCl , 54 mg/d controlled-release [ OROS ] methylphenidate HCl , placebo ) . Study center make every attempt include approximately 4 woman every 10 men randomize . The study consist 3 phase : screen phase 7 day ; 42-day double-blind treatment phase ; 7-day post-treatment phase , investigator staff call patient 7 day last dose study drug , ask adverse event . The total duration patient participation approximately 8 week . During screen double-blind treatment phase , patient periodic assessment visit ( screen , Day 1 , Day 4 , Day 7 , Day 14 , Day 28 , Day 42 ) following : severity ADHD symptom , include inattention impulsivity ; daily function ; sleep experience ; cigarette consumption cigarette crave . In addition , patient ask include adult household member complete observer version Conners Adult ADHD Rating Scale ( CAARS-O : SV ) begin end study . Patients take one oral capsule day morning upon awakening , either JNJ-31001074 ( 1 , 3 , 10 mg ) , match atomoxetine HCL ( 40 80 mg ) , match OROS methylphenidate HCl ( 36 54 mg ) , match placebo . For atomoxetine HCl , patient receive 40 mg/d first 3 day , 80 mg/d remainder study . For OROS methylphenidate HCl , patient receive 36 mg/d first 3 day , 54 mg/d remainder study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Patients diagnose ADHD , confirm Conners Adult ADHD Diagnostic Interview Diagnostic Statistical Manual , 4th edition ( DSMIV ) ( CAADID ) Patients meet cutoff score Conners Adult ADHD Rating Scale ( CAARSS : SV ) Patients Clinical Global Impression Severity ( CGIS ) score &gt; =4 7 Patients must body mass index 18.0 35.0 ( inclusive ) Women must postmenopausal &gt; =2 year , surgically sterile , abstinent , practice doublebarrier method birth control addition form birth control Women childbearing potential must negative pregnancy test screen Men must agree use doublebarrier method birth control donate sperm study 3 month last dose study drug Female partner male patient must postmenopausal , surgically sterile , abstinent , also use effective method birth control . Patients current Axis I psychiatric disorder Patients diagnosis autism Asperger 's syndrome Patients motor tic family history diagnosis Tourette 's syndrome Patients diagnosis primary sleep disorder Patients suicidal previously attempt suicide Patients history substance abuse dependence within 6 month prior screen Patients take mood stabilizer , antipsychotic , antidepressant , anxiolytic within 3 month prior screen Patients start behavioral cognitive behavioral therapy specifically ADHD within 3 month prior screen Patients respond previously treatment psychostimulant medication treatment atomoxetine HCl OROS methylphenidate HCl .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>Attention Deficit Disorders Hyperactivity</keyword>
	<keyword>Adult ADHD</keyword>
	<keyword>JNJ-31001074</keyword>
</DOC>